SPIB, a novel immunohistochemical marker for human blastic plasmacytoid dendritic cell neoplasms: Characterization of its expression in major hematolymphoid neoplasms

Blood

Volumn 121, Issue 4, 2013, Pages 643-647

  Montes Moreno, Santiago ^a   Ramos Medina, Rocio ^b   Martínez López, Azahara ^a   Cornejo, Carlos Barrionuevo ^c   Cubillos, Alejandro Parra ^a   Quintana Truyenque, Shirley ^c   Rodriguez Pinilla, Socorro María ^d   Pajares, Raquel ^b   Sanchez Verde, Lydia ^b   Martinez Torrecuadrada, Jorge ^b   Roncador, Giovanna ^b   Piris, Miguel Angel ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

^c INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS   (Peru)

^d Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD123 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; MONOCLONAL ANTIBODY; SPIB PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; B CELL LYMPHOMA; BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM; CLINICAL ARTICLE; DENDRITIC CELL; DIFFERENTIAL DIAGNOSIS; GENE OVEREXPRESSION; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL LYMPHOMA;

EID: 84873024184     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-08-447599     Document Type: Article

References (20)

1. Schotte R, Rissoan MC, Bendriss-Vermare N, et al. The transcription factor Spi-B is expressed in plasmacytoid DC precursors and inhibits T-, B-, and NK-cell development. Blood. 2003;101(3): 1015-1023.
2. Ray D, Bosselut R, Ghysdael J, Mattei MG, Tavitian A, Moreau-Gachelin F. Characterization of Spi-B, a transcription factor related to the putative oncoprotein Spi-1/PU. 1. Mol Cell Biol. 1992; 12(10):4297-4304.
3. Su GH, Ip HS, Cobb BS, Lu MM, Chen HM, Simon MC. The Ets protein Spi-B is expressed exclusively in B cells and T cells during development. J Exp Med. 1996;184(1):203-214.
4. Su GH, Chen HM, Muthusamy N, et al. Defective B cell receptor-mediated responses in mice lacking the Ets protein, Spi-B. EMBO J. 1997;16(23): 7118-7129.
5. Klein F, Feldhahn N, Mooster JL, et al. Tracing the pre-B to immature B cell transition in human leukemia cells reveals a coordinated sequence of primary and secondary IGK gene rearrangement, IGK deletion, and IGL gene rearrangement. J Immunol. 2005;174(1):367-375.
6. Shaffer AL, Lin KI, Kuo TC, et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity. 2002;17(1):51-62.
7. Schmidlin H, Diehl SA, Nagasawa M, et al. Spi-B inhibits human plasma cell differentiation by repressing BLIMP1 and XBP-1 expression. Blood. 2008;112(5):1804-1812.
8. Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A. 2008;105(36):13520-13525.
9. Lenz G, Nagel I, Siebert R, et al. Aberrant immu-noglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med. 2007;204(3):633-643.
10. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A. 2003;100(17):9991-9996.
11. Yang Y, Shaffer AL, Emre NC, et al. Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma. Cancer Cell. 2012; 21(6):723-737.
12. Karrich JJ, Balzarolo M, Schmidlin H, et al. The transcription factor Spi-B regulates human plas-macytoid dendritic cell survival through direct induction of the antiapoptotic gene BCL2-A1. Blood. 2012;119(22):5191-5200.
13. Dijkman R, van Doorn R, Szuhai K, Willemze R, Vermeer MH, Tensen CP. Gene-expression profiling and array-based CGH classify CD4+CD56+ hematodermic neoplasm and cutaneous myelo-monocytic leukemia as distinct disease entities. Blood. 2007;109(4):1720-1727.
14. Swerdlow S, Campo E, Harris NL, eds; International Agency for Research on Cancer. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Geneva, Switzerland: World Health Organization; 2008.
15. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohisto-chemistry using a tissue microarray. Blood. 2004; 103(1):275-282.
16. Petrella T, Bagot M, Willemze R, et al. Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol. 2005;123(5):662-675.
17. Herling M, Teitell MA, Shen RR, Medeiros LJ, Jones D. TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56 + blastic tumors of skin. Blood. 2003;101(12):5007-5009.
18. Cota C, Vale E, Viana I, et al. Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients. Am J Surg Pathol. 2010;34(1):75-87.
19. Jegalian AG, Buxbaum NP, Facchetti F, et al. Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica. 2010;95(11):1873-1879.
20. Marafioti T, Paterson JC, Ballabio E, et al. Novel markers of normal and neoplastic human plasmacytoid dendritic cells. Blood. 2008;111(7):3778-3792.